Home
Live Updates
Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3 : vimarsana.com
Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3
Revenues of €17.5 million for the full year of 2023, compared to €12.2 million for 2022Cash and cash equivalents at €26.9 million, short-term deposits at € 0.01 million2, and long-term deposit...
Related Keywords
Tianqing ,
Zhejiang ,
China ,
Japan ,
France ,
Israel ,
Daix ,
Bourgogne ,
South Korea ,
Ukraine ,
United States ,
New York ,
Paris ,
France General ,
Boston ,
Massachusetts ,
Russia ,
Chinese ,
French ,
Pascaline Clerc ,
Julia Cailleteau ,
Aude Lepreux ,
Sino Biopharm ,
Chia Tai Tianqing Pharmaceutical Group Co Ltd ,
Exchange Commission ,
Data Monitoring Committee ,
Brunswick Group ,
Corporate Affairs ,
Products Administration ,
Health Care Conference ,
Nasdaq ,
Market Program ,
Hepalys Pharma Inc ,
Patricial Bank ,
European Investment Bank ,
Suspected Unexpected Serious Adverse Reaction ,
Long Island City ,
Euronext Paris ,
Chief Executive Officer ,
Hepalys Pharma ,
Data Monitoring ,
Investigational New Drug ,
Medical Products Administration ,
At The Market Program ,
Hepalys License ,
Informed Consent Form ,
Patient First Visit ,
Annual Health Care Conference ,
Paris Hepatology Conference ,
Annual Conference Liver Connect ,
Nasdaq Global Market ,
Roquet Montegon ,
Private Securities Litigation Reform Act ,
New Drug Application ,
Universal Registration Document ,
Des March ,
Annual Report ,
Half Year Report ,
Markets ,
vimarsana.com © 2020. All Rights Reserved.